NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

TSVT

2seventy bio Inc

May 12 • 04:00PM ET

5.00

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: BLUE NTLA CRSP EDIT PGEN SGMO CLLS RGNX ADAP ALLO

| Held by: VTI VXF VTWO VHT VTWV CHNA XDNA VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.10	Insider Own	9.33%	Shs Outstand	52.47M	Perf Week	0.00%
Market Cap	266.15M	Forward P/E	-	EPS next Y	-0.02	Insider Trans	-76.74%	Shs Float	51.58M	Perf Month	0.81%
Income	-4.09M	PEG	-	EPS next Q	-0.10	Inst Own	85.32%	Short Float	5.03%	Perf Quarter	104.08%
Sales	48.37M	P/S	5.50	EPS this Y	74.55%	Inst Trans	-	Short Ratio	1.85	Perf Half Y	1.01%
Book/sh	4.08	P/B	1.23	EPS next Y	92.86%	ROA	-0.83%	Short Interest	2.59M	Perf Year	11.61%
Cash/sh	3.20	P/C	1.56	EPS next 5Y	-	ROE	-1.94%	52W Range	2.29 - 5.30	Perf YTD	70.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-0.94%	52W High	-5.66%	Beta	1.01
Dividend TTM	-	Quick Ratio	4.80	Sales past 5Y	66.21%	Gross Margin	41.68%	52W Low	118.34%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	4.80	EPS Y/Y TTM	98.22%	Oper. Margin	-122.71%	RSI (14)	72.25	Volatility	0.28% 0.34%
Employees	65	Debt/Eq	1.12	Sales Y/Y TTM	-32.07%	Profit Margin	-8.46%	Recom	3.00	Target Price	5.00
Option/Short	Yes / No	LT Debt/Eq	1.04	EPS Q/Q	100.89%	Payout	-	Rel Volume	0.00	Prev Close	5.00
Sales Surprise	64.28%	EPS Surprise	105.88%	Sales Q/Q	84.46%	Earnings	May 07 AMC	Avg Volume	1.40M	Price	5.00
SMA20	0.25%	SMA50	6.50%	SMA200	23.03%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-24	Downgrade	Goldman	Neutral → Sell	$5 → $2
Jan-31-24	Upgrade	Leerink Partners	Market Perform → Outperform	$5 → $18
Jan-31-24	Downgrade	TD Cowen	Outperform → Market Perform
Oct-30-23	Downgrade	Leerink Partners	Outperform → Market Perform	$6
Oct-12-23	Initiated	Citigroup	Buy	$13
Sep-13-23	Downgrade	Goldman	Buy → Neutral	$5
Sep-12-23	Downgrade	Guggenheim	Buy → Neutral
Jul-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$25 → $13
Oct-31-22	Initiated	Guggenheim	Buy	$30
May-02-22	Initiated	Goldman	Buy	$26
Feb-10-22	Initiated	SVB Leerink	Outperform	$38
Jan-06-22	Initiated	Cowen	Outperform
Nov-09-21	Initiated	Canaccord Genuity	Buy	$42
Nov-08-21	Initiated	Wedbush	Outperform
Nov-08-21	Initiated	Morgan Stanley	Overweight

Show Previous Ratings

May-07-25 04:05PM	2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb (Business Wire)
Apr-17-25 01:06PM	Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings? (Zacks)
Apr-01-25 03:00PM	CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo (Zacks)
Mar-25-25 04:05PM	2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
10:17PM	Loading…
Mar-10-25 10:17PM	2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb (Business Wire) +5.26% +76.79%
Feb-25-25 07:00AM	2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference (Business Wire)
Feb-06-25 07:03AM	2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results (Business Wire) -5.84%
Nov-12-24 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire) -6.96%
Nov-04-24 04:01PM	2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference (Business Wire)
Sep-25-24 06:00AM	2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance (Business Wire) -9.43%
Aug-29-24 07:00AM	2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference (Business Wire) +8.56%
Aug-07-24 07:00AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire) +8.21%
Aug-05-24 07:00AM	2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire)
Jul-05-24 06:45AM	3 Hidden Stock Gems That Wall Street Is Overlooking (InvestorPlace)
04:11PM	Loading…
Jun-26-24 04:11PM	2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million (Business Wire)
May-23-24 07:00AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-08-24 11:57AM	TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace) -9.68%
08:15AM	2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire)
May-03-24 07:00AM	2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-24-24 10:01AM	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.78%
Apr-17-24 11:02AM	2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why (Zacks)
Apr-05-24 09:05AM	U.S. FDA Approves Bristol Myers Squibb and 2seventy bios Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy (Business Wire)
Apr-01-24 07:30AM	2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron (Business Wire) +8.22%
Mar-20-24 05:04PM	2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors (Business Wire) +9.91%
Mar-15-24 06:27PM	FDA Advisory Committee Votes in Favor of Bristol Myers Squibbs and 2seventy bios Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy (Business Wire)
Mar-07-24 09:10AM	2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.11%
Mar-05-24 07:53AM	TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +6.83%
07:00AM	Loading…
07:00AM	2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress (Business Wire)
Mar-04-24 08:56AM	Should You Buy 2seventy bio (TSVT) Ahead of Earnings? (Zacks)
Mar-01-24 07:00AM	2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences (Business Wire) +8.46%
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile) +8.36%
Feb-05-24 04:05PM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire) +7.62%
06:59AM	Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study (Business Wire)
Feb-01-24 08:27AM	2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains? (Zacks)
Jan-31-24 11:11AM	2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up (Zacks) +28.18%
Jan-30-24 07:01AM	2seventy bio Announces New Strategic Path Forward (Business Wire) +14.90%
Jan-12-24 12:00PM	All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy (Zacks)
Dec-11-23 07:30PM	Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3 (Business Wire)
07:00AM	2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel) (Business Wire)
Dec-06-23 02:00PM	2seventy bio Reiterates Commitment to Maximizing Shareholder Value (Business Wire) +9.30%
Nov-20-23 12:02PM	Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug (Investopedia) -18.31%
06:59AM	Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma (Business Wire)
Nov-14-23 07:00AM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire)
Nov-10-23 07:00AM	2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023 (Business Wire)
Sep-12-23 07:00AM	2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway (Business Wire) -5.02%
06:55AM	2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies (Business Wire)
Sep-06-23 07:00AM	2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-24-23 09:00PM	CFO Baird William D III Sells 7,031 Shares of 2seventy bio Inc (TSVT) (GuruFocus.com)
Aug-14-23 07:00AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
Aug-08-23 07:00AM	2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023 (Business Wire)
Aug-01-23 04:15PM	2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference (Business Wire) -8.56% -7.06%
Jun-14-23 07:00AM	2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia (Business Wire) -8.98%
Jun-07-23 07:00AM	2seventy bio to Participate in Upcoming Investor Conference (Business Wire)
May-19-23 06:00AM	2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia (Business Wire)
May-17-23 07:17AM	2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio (Business Wire)
May-11-23 12:37PM	2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023 (Business Wire)
May-03-23 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire) +14.53%
May-02-23 04:37PM	2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting (Business Wire)
10:00AM	Billionaire Ken Griffin Doubles Down on These 2 Strong Buy Stocks Heres Why You Might Want to Follow in His Footsteps (TipRanks)
May-01-23 07:00AM	2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program (Business Wire) +8.31%
Apr-28-23 08:30AM	2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire) +5.78%
Apr-17-23 06:59AM	Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma (Business Wire)
Mar-16-23 04:05PM	2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress (Business Wire)
Mar-08-23 08:30AM	2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors (Business Wire)
Mar-03-23 07:00AM	2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference (Business Wire)
Mar-01-23 09:00AM	Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer (PR Newswire) -18.38%
Feb-28-23 09:00PM	2seventy bio Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
04:01PM	2seventy bio Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-10-23 11:13AM	Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study (Business Wire)
Feb-01-23 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jan-18-23 11:35AM	Medigene Receives $3 Million Milestone Payment from 2seventy bio (GlobeNewswire)
Jan-09-23 08:00AM	2seventy bio Provides Company Outlook for 2023 (Business Wire)
Jan-06-23 09:11AM	2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors (Business Wire)
Nov-07-22 04:05PM	2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress (Business Wire) +6.78%
Nov-03-22 09:06AM	2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-27-22 07:00AM	2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies (Business Wire)
Sep-07-22 07:00AM	2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients (Business Wire) +5.76%
Aug-31-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-22 06:23AM	2seventy bio, Inc. (NASDAQ:TSVT) Analysts Just Slashed This Year's Revenue Estimates By 12% (Simply Wall St.)
Aug-10-22 06:50AM	2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress (Business Wire)
06:45AM	Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma (Business Wire)
Aug-04-22 07:02AM	Will 2seventy bio (NASDAQ:TSVT) Spend Its Cash Wisely? (Simply Wall St.)
Aug-03-22 07:30AM	2seventy bio to Participate in Upcoming Investor Conferences (Business Wire)
Jul-04-22 03:30PM	A 2seventy bio, Inc. (NASDAQ:TSVT) insider increased their holdings by 251% last year (Simply Wall St.)
Jun-06-22 07:30AM	2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference (Business Wire)
May-12-22 04:05PM	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress (Business Wire) +6.05%
May-04-22 09:10PM	Goldman Sachs Sees These 2 Strong Buy Stocks Skyrocketing Over 70% (TipRanks) +5.65% -7.53%
Apr-08-22 04:15PM	2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting (Business Wire)
Apr-07-22 07:30AM	2seventy bio to Participate in CG Horizons in Oncology Virtual Conference (Business Wire)
Mar-22-22 07:00AM	2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress (Business Wire) +5.28%
Mar-16-22 08:41AM	2seventy bio Secures $170 Million in Private Placement Equity Financing (Business Wire) +14.59%
Feb-14-22 07:30AM	2seventy bio Announces Key Management Appointments (Business Wire)
07:00AM	2seventy bio to Participate in Upcoming Healthcare Conferences (Business Wire)
Feb-11-22 09:58AM	Do Institutions Own 2seventy bio, Inc. (NASDAQ:TSVT) Shares? (Simply Wall St.) -5.84%
Feb-03-22 01:38PM	Virginia Retirement Systems Et Al Buys Wolfspeed Inc, Orion Office REIT Inc, Kyndryl Holdings ... (GuruFocus.com)
Jan-26-22 08:00AM	Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer (GlobeNewswire) -9.53%
Jan-11-22 07:00AM	2seventy bio Shares Key Milestones and Business Updates for 2022 (Business Wire)

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Snow Jessica	Chief Operating Officer	Mar 17 '25	Sale	4.95	2,298	11,364	254,193	Mar 19 04:49 PM
Baird William D III	President and CEO	Mar 17 '25	Sale	4.95	5,092	25,180	1,121,034	Mar 19 04:48 PM
Eatwell Victoria	Chief Financial Officer	Mar 17 '25	Sale	4.95	2,592	12,817	444,387	Mar 19 04:48 PM
Kynam Global Healthcare Master	10% Owner	Mar 11 '25	Sale	4.93	11,095,936	54,702,964	0	Mar 13 06:18 PM
Kynam Global Healthcare Master	10% Owner	Mar 11 '25	Sale	4.93	5,142,111	25,350,607	0	Mar 13 06:18 PM
Snow Jessica	See Remarks	Jan 06 '25	Sale	2.79	5,114	14,289	147,365	Jan 07 04:42 PM
Snow Jessica	See Remarks	Jan 03 '25	Sale	2.94	1,000	2,936	152,479	Jan 07 04:42 PM
Snow Jessica	See Remarks	Jan 07 '25	Sale	2.64	186	491	147,179	Jan 07 04:42 PM
Leschly Nick	Director	Jan 03 '25	Sale	2.94	85,978	252,423	1,234,498	Jan 07 04:42 PM
Leschly Nick	Director	Jan 06 '25	Sale	2.78	892	2,478	1,233,606	Jan 07 04:42 PM
Eatwell Victoria	Chief Financial Officer	Jan 03 '25	Sale	2.94	1,013	2,974	339,076	Jan 07 04:42 PM
Eatwell Victoria	Chief Financial Officer	Jan 06 '25	Sale	2.78	97	270	338,979	Jan 07 04:42 PM
Baird William D III	President and CEO	Jan 03 '25	Sale	2.94	31,718	93,121	862,889	Jan 07 04:41 PM
Baird William D III	President and CEO	Jan 06 '25	Sale	2.78	763	2,120	862,126	Jan 07 04:41 PM
Snow Jessica	See Remarks	Dec 13 '24	Sale	3.23	2,287	7,393	153,479	Dec 17 04:11 PM
JESSICA C SNOW	Officer	Dec 13 '24	Proposed Sale	3.34	10,341	34,539		Dec 13 04:26 PM
Maus Marcela V.	Director	Nov 18 '24	Sale	3.38	3,900	13,182	23,752	Nov 20 04:12 PM
MARCELA MAUS	Director	Nov 18 '24	Proposed Sale	3.38	3,900	13,182		Nov 18 04:50 PM
Snow Jessica	See Remarks	Aug 14 '24	Sale	4.32	7,816	33,760	156,330	Aug 16 05:10 PM
JESSICA SNOW	Officer	Aug 14 '24	Proposed Sale	4.32	7,816	33,760		Aug 14 05:19 PM
Eatwell Victoria	Chief Financial Officer	Aug 05 '24	Sale	3.98	13	52	341,319	Aug 07 04:56 PM
Snow Jessica	See Remarks	Jul 02 '24	Sale	4.02	14	56	164,146	Jul 03 04:14 PM
Eatwell Victoria	Chief Financial Officer	Jul 02 '24	Sale	4.02	12	48	341,332	Jul 03 04:14 PM
Eatwell Victoria	Chief Financial Officer	Jun 03 '24	Sale	4.18	1,167	4,881	95,480	Jun 05 07:16 PM
Snow Jessica	See Remarks	Jun 03 '24	Sale	4.18	649	2,714	55,622	Jun 05 07:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TSVT

2seventy bio Inc

Upgrade your FINVIZ experience